https://www.selleckchem.com/pr....oducts/mdl-28170.htm
LIF's anti-CSC effect was reversed by XMU-MP-1 but not by Ruxolitinib treatment, highlighting the opposite effects of these two pathways downstream LIFR. In conclusion, LIF displays anti-CSC properties in GC, through Hippo kinases activation, and could in fine constitute a new CSCs-targeting strategy to help decrease relapse cases and bad prognosis in GC.Since the discovery of high-temperature superconductivity, significant progress in the fabrication of REBCO-based (Rare Earth Barium Copper mixed Oxides) thin-films superconductors ha
Curtir
Comentario
Compartilhar
